Peritonitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Peritonitis - Pipeline Review, H1 2016', provides an overview of the Peritonitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peritonitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peritonitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Peritonitis - The report reviews pipeline therapeutics for Peritonitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Peritonitis therapeutics and enlists all their major and minor projects - The report assesses Peritonitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Peritonitis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Peritonitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Peritonitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Peritonitis Overview 6 Therapeutics Development 7 Pipeline Products for Peritonitis - Overview 7 Pipeline Products for Peritonitis - Comparative Analysis 8 Peritonitis - Therapeutics under Development by Companies 9 Peritonitis - Therapeutics under Investigation by Universities/Institutes 10 Peritonitis - Pipeline Products Glance 11 Early Stage Products 11 Peritonitis - Products under Development by Companies 12 Peritonitis - Products under Investigation by Universities/Institutes 13 Peritonitis - Companies Involved in Therapeutics Development 14 GlaxoSmithKline Plc 14 Oncodesign SA 15 Tobira Therapeutics, Inc. 16 Peritonitis - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 25 AcPepA - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 cenicriviroc mesylate - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ECL-1 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 SRT-3025 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Peritonitis - Recent Pipeline Updates 32 Peritonitis - Dormant Projects 37 Peritonitis - Product Development Milestones 38 Featured News & Press Releases 38 Mar 20, 2015: Tobira Therapeutics Highlights Presentations at the AASLD's Industry Colloquium for Novel Targets and Therapies in Liver Disease 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 39 Disclaimer 40
List of Tables
Number of Products under Development for Peritonitis, H1 2016 7 Number of Products under Development for Peritonitis - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Products under Investigation by Universities/Institutes, H1 2016 13 Peritonitis - Pipeline by GlaxoSmithKline Plc, H1 2016 14 Peritonitis - Pipeline by Oncodesign SA, H1 2016 15 Peritonitis - Pipeline by Tobira Therapeutics, Inc., H1 2016 16 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Stage and Target, H1 2016 19 Number of Products by Stage and Mechanism of Action, H1 2016 21 Number of Products by Stage and Route of Administration, H1 2016 23 Number of Products by Stage and Molecule Type, H1 2016 24 Peritonitis Therapeutics - Recent Pipeline Updates, H1 2016 32 Peritonitis - Dormant Projects, H1 2016 37
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.